el maghraoui, abdellah hôpital militaire d’instruction mohammed v - service de rhumatologie, Rabat, Morocco

Place of risedronate in the treatment of osteoporosis

32127

Bisphosphonates have been considered for many years as the first-line treatment for postmenopausal osteoporosis. They are powerful inhibitors of bone resorption. Risedronate is an oral bisphosphonate (35 mg weekly) that has been shown to reduce the risk of vertebral and non-vertebral fractures in osteoporotic patients in both postmenopausal osteoporosis and in corticosteroid induced osteoporosis. Compared with alendronate, risedronate is characterized by a faster onset of action after six months of treatment which rapidly fades within six months of discontinuation (no residual effect). It is very well tolerated both in the short and long term.

25

Osteoporosis , Risedronate , Efficacy , Side effects

Revue Marocaine De Rhumatologie

30